Precigen, Inc. (PGEN) Poised for Growth on Respiratory Papillomatosis Treatment Prospects

Precigen Inc. (NASDAQ:PGEN) is one of the best multibagger penny stocks to invest in. On March 26, analysts at Citizens reiterated a Market Outperform rating on Precigen Inc. (NASDAQ:PGEN) and hiked the price target to $9 from $8.

Precigen, Inc. (PGEN) Poised for Growth on Respiratory Papillomatosis Treatment Prospects

The price target hike underscores the research firm’s confidence in the company’s lead drug, PAPZIMEOS, as a frontline standard of care for recurrent respiratory papillomatosis. The drug received full FDA approval last year as the first immunotherapy for recurrent respiratory papillomatosis. Management has already indicated that they are on course to generate more than $18 million in PAPZIMEOS sales in the first quarter.

Citizen’s is confident sales will exceed guidance, given solid commercial metrics, including patient engagement and enrollment in hubs. Engaged patient profiles for papillomatosis are broad, including patients who have undergone many surgeries. The company remains well-positioned to capitalize on PAPZIMEOS edge as the first and only approved therapy for recurrent respiratory papillomatosis.

Precigen, Inc. (NASDAQ:PGEN) is a clinical-stage biopharmaceutical company focused on developing next-generation gene and cell therapies, specifically in immuno-oncology, autoimmune disorders, and infectious diseases.

While we acknowledge the risk and potential of PGEN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PGEN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Motley Fool’s 10 High-Growth Stock Picks and 8 Best Blue Chip AI Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.